DiscoveRx : A leader in cell-based assays for GPCR, Kinases and NHR

publication date: Nov 11, 2008

DiscoveRx announced that it’s PathHunter™ and HitHunter™ lines of GPCR products are the recipient of the 2008 European Cell-Based Assays Product Line Strategy Award from Frost and Sullivan. DiscoveRx, a leader in G protein-coupled receptors (GPCRs) is recognized for its broad, yet distinctive, portfolio of cell-based assay products that have received outstanding recognition from leading life science organizations.

"DiscoveRx is acknowledged as one of the most active participants in the functional assay market as reflected in the company's continuous efforts in technology innovation such as the PathHunter™ Arrestin technology and the HitHunter™ cAMP Assay; GPCR assay platform, helping to accelerate the discovery of new drug candidates," notes Frost & Sullivan Research Analyst Laleh Safinia. "Having an expanding pipeline of highly promising products, combined with top-quality management and sales, DiscoveRx continues to improve its standing in the functional assay area, influencing the direction of drug discovery."

Founded in 2000, DiscoveRx has pioneered the use of ß-galactosidase enzyme fragment complementation in biochemical and cell-based assays for drug discovery research, holding extensive intellectual property in this area. The company is devoted to the development and commercialization of functional assays to study GPCRs, kinases and NHR, with many of their innovative products adopted in pharmaceutical and biotech drug screening laboratories globally.

"To meet the growing demand of functional assays during screening, DiscoveRx has announced the growing list of GPCRs representing 32 ligand families based on the PathHunter™ Arrestin technology, which measures GPCR activation without the need for target over expression, force coupling, imaging or second messenger detection," remarks Safinia.

"Such activities further reinforce the fact that DiscoveRx is actively seeking to commercialize and provide early access to new technology platforms in the drug discovery market," states Safinia. "Frost and Sullivan salutes the product line enhancement strategies adopted by the firm and strongly believes that DiscoveRx will continue to enhance its standing in the functional assay area."

The Frost & Sullivan Award for Product Line Strategy is presented each year to a company that has demonstrated the most insight into customer needs and product demands. The recipient company should have optimized its product line by leveraging products with the various price, performance, and feature points required by the market.

www.discoverx.com